Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Farshid, Sadeghipour"'
Publikováno v:
Health Economics Review, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Background Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases. However, their introduction into hospital formularies through initiatives such as non-m
Externí odkaz:
https://doaj.org/article/744f7b70455545c2b046e2d52499261a
Autor:
Alma Feka, Ermindo R. Di Paolo, Jean-Yves Pauchard, Alexandra Mariguesa, Mario Gehri, Farshid Sadeghipour
Publikováno v:
Swiss Medical Weekly, Vol 152, Iss 0506 (2022)
BACKGROUND: The high off-label use of drugs in paediatric patients raises questions on the efficacy and safety when prescribing psychotropic drugs. In our studies, we aimed to characterise the use of psychotropic drugs in the paediatric service of a
Externí odkaz:
https://doaj.org/article/188bfd8db660427ba84ad06ea2df9b4e
Autor:
Christel Bruggmann, Julien Adjedj, Sylvain Sardy, Olivier Muller, Pierre Voirol, Farshid Sadeghipour
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 8, p e21938 (2021)
BackgroundSecondary prevention strategies after acute coronary syndrome (ACS) presentation with the use of drug combinations are essential to reduce the recurrence of cardiovascular events. However, lack of drug adherence is known to be common in thi
Externí odkaz:
https://doaj.org/article/1a929c8ed2de493883f352b34a26e15f
Adequacy of stress ulcer prophylaxis prescription in the intensive care unit: an observational study
Autor:
Marilena Franchitti, Jitka Piubellini, Farshid Sadeghipour, Philippe Eckert, Pierre Voirol, Antoine G. Schneider
Publikováno v:
Swiss Medical Weekly, Vol 150, Iss 3536 (2020)
PURPOSE Stress ulcer prophylaxis prescriptions might not be sufficiently challenged throughout a patient's stay in an intensive care unit (ICU) and might be erroneously maintained after ICU discharge. This study aimed to determine (1) stress ulcer p
Externí odkaz:
https://doaj.org/article/004d0f0e19134e1d808b38ce1ce2de89
Autor:
Christel Bruggmann, Stéphane Fournier, Alice Panchaud, Olivier Muller, Farshid Sadeghipour, Pierre Voirol
Publikováno v:
Swiss Medical Weekly, Vol 150, Iss 3334 (2020)
BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI). Evidence for beta-blocker indication depends on the presence of left ventricular dysfunction (left ventricul
Externí odkaz:
https://doaj.org/article/13f8d99b257046f5b5927f3d23566f56
Publikováno v:
Healthcare; Volume 10; Issue 11; Pages: 2152
Tumor necrosis factor-alpha (TNF-⍺) antagonists are biological drugs with multiple authorized biosimilars. Biosimilars are becoming critical to the financial sustainability of health systems. Recent studies emphasize that physicians’ knowledge re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::a6750acbfa8c7c7a0ea2218a90bf43dc
Autor:
Isabelle Sommer, Lucie Bouchoud, Pascal Bonnabry, D Palmero, Farshid Sadeghipour, Céline J. Fischer Fumeaux
Publikováno v:
Therapeutics and Clinical Risk Management
Isabelle Sommer,1– 4 David Palmero,1 Céline Julie Fischer Fumeaux,5 Pascal Bonnabry,3,4,6 Lucie Bouchoud,6 Farshid Sadeghipour1– 4 1Service of Pharmacy, Lausanne University Hospital, Lausanne, Switzerland; 2Center for Research and Innovation in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd37507272e2e6399f31b62aff684cd
http://europepmc.org/articles/PMC8169048
http://europepmc.org/articles/PMC8169048
Autor:
Adèle Rakotonirina, Tatiana Galperine, Maxime Audry, Marie Kroemer, Aurélie Baliff, Laurent Carrez, Farshid Sadeghipour, Jacques Schrenzel, Benoît Guery, Eric Allémann
Publikováno v:
International Journal of Pharmaceutics. 639:122961
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48790b8a97364bbd9d7023ca982c6fe8
https://doi.org/10.1016/j.ijpharm.2023.122961
https://doi.org/10.1016/j.ijpharm.2023.122961
Autor:
Aurélie Ballif, Susanna Gerber, Laurent Carrez, Maxime Audry, Farshid Sadeghipour, Alexandra Mitouassiwou, Antony Croxatto, Onya Opota, Guy Prod’hom, Sarah Henchoz, Alain Schoepfer, Matthias Cavassini, Tatiana Galpérine
Publikováno v:
Revue Médicale Suisse. 17:726-731
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbb746edf574ae8e606737d996cb5e54
https://doi.org/10.53738/revmed.2021.17.734.0726
https://doi.org/10.53738/revmed.2021.17.734.0726
Publikováno v:
Drugs - real world outcomes. 9(3)
CT-P13 is an infliximab biosimilar that was granted market authorization in Switzerland in 2016. Despite the growing literature supporting the equivalence of CT-P13 compared with originator infliximab regarding the efficacy, safety, and immunogenicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a575da9acf31a97b1d2516da690d7c2
https://pubmed.ncbi.nlm.nih.gov/35590047
https://pubmed.ncbi.nlm.nih.gov/35590047